INVO Fertility, Inc (NASDAQ:IVF) Short Interest Update

INVO Fertility, Inc (NASDAQ:IVF) was the target of a significant increase in short interest in the month of August. As of August 31st, there was short interest totaling 367,548 shares, an increase of 60.9% from the August 15th total of 228,460 shares. Currently, 14.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 11,714,828 shares, the short-interest ratio is presently 0.0 days.

INVO Fertility Stock Performance

NASDAQ IVF opened at $0.93 on Friday. The firm’s 50 day simple moving average is $1.04 and its 200 day simple moving average is $1.81. The firm has a market capitalization of $2.33 million, a price-to-earnings ratio of -0.03 and a beta of 2.34. The company has a current ratio of 0.71, a quick ratio of 0.67 and a debt-to-equity ratio of 0.03. INVO Fertility has a 1 year low of $0.90 and a 1 year high of $84.40.

INVO Fertility (NASDAQ:IVF) last announced its quarterly earnings data on Friday, August 14th. The company reported $0.35 EPS for the quarter. The business had revenue of $2.18 million during the quarter. INVO Fertility had a negative net margin of 116.29% and a negative return on equity of 85.54%.

Wall Street Analyst Weigh In

Several brokerages have weighed in on IVF. Wall Street Zen raised INVO Fertility to a “hold” rating in a report on Saturday, August 29th. Weiss Ratings restated a “sell (e+)” rating on shares of INVO Fertility in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, INVO Fertility has an average rating of “Moderate Buy” and an average price target of $20.00.

About INVO Fertility

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.